Fulcrum Therapeutics, Inc.
FULCNext catalyst
No upcoming catalyst in our data
No upcoming FDA decision, filing or trial readout is on file for FULC. That does not mean none is planned.
Get an email about FULC's next catalysts
Track Fulcrum Therapeutics (FULC) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
0 upcoming, 1 past
No catalysts found.
Market Overview
Stock performance and key metrics
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Losmapimod oral tablet | Phase 2 | Facioscapulohumeral Muscular Dystrophy (FSHD) | - | - |
Frequently asked questions
What is in Fulcrum Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 1 drug candidate in Fulcrum Therapeutics, Inc.'s (FULC) pipeline across Phase 2. Its lead program is Losmapimod oral tablet (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Fulcrum Therapeutics, Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Fulcrum Therapeutics, Inc. (FULC) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track FULC biotech catalysts?→
Add FULC to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Fulcrum Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.